ESMO E-Learning: Future Directions in Clinical Research of NSCLC
- To be familiar with novelties in the molecular classification of non-small cell lung cancer evolving from deeper understanding in molecular biology of cancer
- To gain knowledge on developmental therapeutics for heterogeneous group of tumours that belong to an old term category of non-small cell lung cancer
- To understand future research directions and potentials for changing the clinical landscape in non-small cell lung cancer by novel targeted agents and immunotherapeutics
|Title||Duration||Content||CME Points||CME Test|
|Future Directions in Clinical Research of NSCLC||29 min.||84 slides||1||Take Test|
This E-learning module reviews the new molecular landscape and emerging directions in clinical research of non-small-cell lung cancer (NSCLC). NSCLC has evolved into a heterogeneous group of diseases with different molecular characteristics and therefore, targeting molecular aberrations is a major therapeutic strategy. Re-biopsy on progression and re-genotyping to facilitate personalised therapy have been shown as a valid research strategy. In addition, immunotherapy represents a novel research paradigm in NSCLC, but vaccination therapy has not been proven effective yet, although immune check-point inhibitors showed great promise.
In this module, the author discusses developmental therapeutics for EGFR mutation-positive, KRAS mutation-positive, ALK fusion-positive, HSP90, ROS1 fusion-positive, BRAF activating and inactivating mutation-positive, FGFR amplified, DDR2 mutation-positive, RET fusion-positive subsets of NSCLC, vaccines and anti-PD1/L1 immunotherapeutics.
The module covers:
- First-, second- and third-generation of tyrosine kinase inhibitors in EGFR mutant NSCLC and putative resistance mechanisms, including EGFR T790M and MET amplification
- Systemic therapy in patients with KRAS mutant NSCLC
- ALK kinase inhibitors in ALK and ROS fusion-positive NSCLC, research on mechanisms of resistance and future directions in ALK-directed therapy.
- BRAF inhibitors in patients with BRAF V600E mutations
- Targeting rarer somatic aberrations including EGFR amplification, DDR2 mutations and RET fusion
- Immunotherapy strategies with vaccines and immune checkpoint inhibitors
This E-learning module shows how personalised treatment evolves from the deeper understanding of NSCLC tumours biology and how one cancer type, considered as a big killer in oncology, is transforming into subgroups of different, rare entities. It is an excellent CME opportunity for all those interested in the latest research advances and potential therapeutic opportunities in the near future, as clinical development programmes are rapidly evolving.
The author has reported to be a non-reimbursed consultant to AstraZeneca, Boehringer, Roche, Lilly, Novartis, Pfizer. His institution has received research funding from Pierre Fabre and Otsuka.